Login to Your Account



ODAC says yes to Hospira biosimilar, urges vigilance

By Mari Serebrov
Regulatory Editor

Thursday, May 25, 2017

With an FDA advisory committee voting 14-1 Thursday to recommend licensure of Hospira Inc.'s epoetin biosimilar, the U.S. is one step closer to catching up with other markets that are nearly a decade ahead on the biosimilar path.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription